CD68 and CD83 immune populations in non-metastatic axillary lymph nodes are of prognostic value for the survival and relapse of breast cancer patients

Identificador:  imarina:9244737

Handle: https://hdl.handle.net/20.500.11797/imarina9244737

Autores:  López, C; Bosch, R; Korzynska, A; García-Rojo, M; Bueno, G; García-Fontgivell, JF; González, SM; Navarro, AG; Colón, ES; Ribes, JC; Roszkowiak, L; Mata, D; Arenas, M; Gómez, J; Roso, A; Berenguer, M; Reverté-Villarroya, S; Llobera, M; Baucells, J; Lejeune, M

Resumen:
The foremost cause of death of breast cancer (BC) patients is metastasis, and the first site to which BC predominantly metastasizes is the axillary lymph node (ALN). Thus, ALN status is a key prognostic indicator at diagnosis. The immune system has an essential role in cancer progression and dissemination, so its evaluation in ALNs could have significant applications. In the present study we aimed to investigate the association of clinical-pathological and immune variables in the primary tumour and non-metastatic ALNs (ALNs-) of a cohort of luminal A and triple-negative BC (TNBC) patients with cancer-specific survival (CSS) and time to progression (TTP).We analysed the differences in the variables between patients with different outcomes, created univariate and multivariate Cox regression models, validated them by bootstrapping and multiple imputation of missing data techniques, and used Kaplan-Meier survival curves for a 10-years follow-up.We found some clinical-pathological variables at diagnosis (tumour diameter, TNBC molecular profile and presence of ALN metastasis), and the levels of several immune markers in the two studied sites, to be associated with worse CSS and TTP. Nevertheless, only CD68 and CD83 in ALNs- were confirmed as independent prognostic factors for TTP.The study identified the importance of macrophage and dendritic cell markers as prognostic factors of relapse for BC. We highlight the importance of studying the immune response in ALNs-, which could be relevant to the prediction of BC patients' outcome.© 2022. The Author(s), under exclusive licence to The Japanese Breast Cancer Society.